DnB Asset Management AS Has $6.07 Million Holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

DnB Asset Management AS grew its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 1.8% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 14,675 shares of the company’s stock after buying an additional 254 shares during the period. DnB Asset Management AS’s holdings in IDEXX Laboratories were worth $6,067,000 as of its most recent filing with the SEC.

Several other large investors also recently modified their holdings of IDXX. Norges Bank acquired a new stake in IDEXX Laboratories in the fourth quarter worth $412,258,000. Flossbach Von Storch SE boosted its position in shares of IDEXX Laboratories by 5,439.3% during the 4th quarter. Flossbach Von Storch SE now owns 473,336 shares of the company’s stock worth $195,696,000 after purchasing an additional 464,791 shares in the last quarter. William Blair Investment Management LLC grew its stake in shares of IDEXX Laboratories by 701.6% in the 4th quarter. William Blair Investment Management LLC now owns 422,133 shares of the company’s stock valued at $174,527,000 after buying an additional 369,471 shares during the period. Assenagon Asset Management S.A. increased its position in IDEXX Laboratories by 265.6% in the 4th quarter. Assenagon Asset Management S.A. now owns 435,049 shares of the company’s stock valued at $179,867,000 after buying an additional 316,048 shares in the last quarter. Finally, Seilern Investment Management Ltd bought a new stake in IDEXX Laboratories in the 4th quarter valued at about $113,104,000. Institutional investors and hedge funds own 87.84% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have commented on IDXX shares. Morgan Stanley reduced their price objective on IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating for the company in a research note on Wednesday, January 29th. StockNews.com downgraded shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Tuesday, March 25th. Piper Sandler raised their price objective on shares of IDEXX Laboratories from $435.00 to $510.00 and gave the company a “neutral” rating in a research note on Monday, February 10th. Leerink Partnrs raised shares of IDEXX Laboratories to a “strong-buy” rating in a research report on Monday, December 2nd. Finally, Barclays raised their price target on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the company an “overweight” rating in a research report on Tuesday, February 4th. Four investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $533.75.

Insider Buying and Selling

In other IDEXX Laboratories news, EVP George Fennell sold 9,986 shares of the stock in a transaction on Monday, February 10th. The stock was sold at an average price of $462.53, for a total transaction of $4,618,824.58. Following the completion of the transaction, the executive vice president now directly owns 8,176 shares of the company’s stock, valued at approximately $3,781,645.28. This represents a 54.98 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director M Anne Szostak sold 3,000 shares of the company’s stock in a transaction on Friday, February 7th. The shares were sold at an average price of $465.94, for a total value of $1,397,820.00. Following the transaction, the director now directly owns 3,061 shares in the company, valued at $1,426,242.34. This represents a 49.50 % decrease in their position. The disclosure for this sale can be found here. 2.11% of the stock is owned by insiders.

IDEXX Laboratories Stock Down 1.6 %

IDXX stock opened at $415.87 on Monday. The stock has a market cap of $33.71 billion, a P/E ratio of 38.98, a P/E/G ratio of 3.41 and a beta of 1.39. The company has a current ratio of 1.31, a quick ratio of 0.95 and a debt-to-equity ratio of 0.28. The stock’s fifty day simple moving average is $437.07 and its two-hundred day simple moving average is $442.57. IDEXX Laboratories, Inc. has a 1-year low of $398.50 and a 1-year high of $548.88.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.